Wyeth-Ayerst Crinone comparative claims in press release are misleading -- FDA ad division.
Executive Summary
WYETH-AYERST CRINONE PRESS RELEASE DISSEMINATION DESPITE DDMAC WARNING draws May 19 letter from FDA's Division of Drug Marketing, Advertising & Communications to Wyeth-Ayerst Associate Director of Regulatory Affairs Joan Barton. DDMAC Regulatory Review Officer Lisa Stockbridge, PhD, reminded Barton: "I told you that I had concerns about at least one presentation before I had finished the first read of the press release."